Zantac carcinogen: CVS Pharmacy pulls Zantac and the generic brand ranitidine over possible link to cancer

Zantac pulled by CVS over known carcinogen

CVS Pharmacy announced that it withdrew heartburn medicine Zantac from its shelves over a possible link to cancer . The popular non-prescription drug and CVS & # 39; s own generic brand – ranitidine – will not be put into stores going forward after trace amounts of a known carcinogen were found by health officials.

An official recall of Zantac has not been issued, reports CBS New York.

Earlier this month the Food and Drug Administration (FDA) said that some of the pills being tested contained small amounts of N-nitrosodimethylamine (NDMA).

NDMA can be harmful in large quantities, but the levels the FDA found in preliminary tests of ranitidine "barely exceed the amounts you can expect to find in regular foods," according to a statement by Dr. Janet Woodcock, research director of the agency's Centers for Drug Evaluation and Research.

The FDA said people should not panic, but suggests switching to another drug without medication while the agency is testing more samples.

Drugmaker Novartis had already announced that it will no longer distribute generic versions of Zantac due to the discovery. Sandoz, the Novartis division that makes a generic version of Zantac, said it "has not received any reports of adverse events related to the use of the product as part of this recall. Patients should consult a physician or pharmacist for alternative treatment options." [19659006] Sanofi, the company that makes the name-brand Zantac medication, released this statement on Saturday:

The FDA reported that levels of N-nitrosodimethylamine (NDMA) in ranitidine in preliminary tests barely exceed amounts found in common foods. We work closely with the FDA and conduct our own robust investigations to ensure that we continue to meet the highest quality standards for safety and quality. At Sanofi, we are still committed to being transparent with our patients and consumers and will share an update when available. There are currently no plans to stop distributing or producing Zantac or other ranitidine products outside Canada.

Packages and pills with Zantac sitting on a table. The FDA suggests people switch to another medicine without medicine while the agency is testing more samples.


Source link

Back to top button